Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Clin Pharmacol Ther. 2014 Apr 29;96(2):182–191. doi: 10.1038/clpt.2014.93

Figure 1. Pharmacokinetics and Impact of Smoking for Erlotinib (OSI-774) and OSI-420.

Figure 1

Semi-log concentration vs. time plots of erlotinib (panels A and B) and OSI-420 (panels C and D). Each compound was simultaneously measured with a validated LC/MS/MS assay in patient plasma samples up to 24 hours after the first dose in cycle 1 (panels A and C) and cycle 2 (panels B and D). Dot plots showing smoking status vs. (E) erlotinib (OSI-774) and (F) OSI-420 AUC during cycle 1.